Asenapine sensitization from adolescence to adulthood and its potential molecular basis

Qing Shu, Rongyin Qin, Yingzhu Chen, Gang Hu, Ming Li

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Asenapine is a new antipsychotic drug that induces a long-lasting behavioral sensitization in adult rats. The present study investigated the developmental impacts of adolescent asenapine treatment on drug sensitivity and on 3 proteins implicated in the action of antipsychotic drugs (i.e. brain-derived neurotrophic factor (BDNF), dopamine D2 receptor, and δFosB) in adulthood. Male adolescent Sprague-Dawley rats (postnatal days, P 43-48) were first treated with asenapine (0.05, 0.10 or 0.20mg/kg, sc) and tested in the conditioned avoidance or PCP (2.0mg/kg, sc)-induced hyperlocomotion tasks for 5 days. After they became adults (~P 76), asenapine sensitization was assessed in a single avoidance or PCP-induced hyperlocomotion challenge test with all rats being injected with asenapine (0.10mg/kg, sc). Rats were then sacrificed 1 day later and BDNF, D2 and δFosB in the prefrontal cortex, striatum and hippocampus were examined using Western blotting. In adolescence, repeated asenapine treatment produced a persistent and dose-dependent inhibition of avoidance response, spontaneous motor activity and PCP-induced hyperlocomotion. In the asenapine challenge test, adult rats treated with asenapine (0.10 and 0.20mg/kg) in adolescence made significantly fewer avoidance responses and showed a stronger inhibition of spontaneous motor activity than those previously treated with saline. However, no group difference in the levels of BDNF, D2 and δFosB expression was found. These findings suggest that although adolescent asenapine treatment for a short period of time induces a robust behavioral sensitization that persists into adulthood, such a long-term effect is not likely to be mediated by BDNF, D2 and δFosB.

Original languageEnglish (US)
Pages (from-to)166-176
Number of pages11
JournalBehavioural Brain Research
Volume273
DOIs
StatePublished - Oct 15 2014

Fingerprint

Brain-Derived Neurotrophic Factor
Antipsychotic Agents
Motor Activity
Asenapine
Dopamine D2 Receptors
Prefrontal Cortex
Sprague Dawley Rats
Hippocampus
Therapeutics
Western Blotting
Pharmaceutical Preparations
Proteins
Inhibition (Psychology)

Keywords

  • Asenapine
  • BDNF
  • Conditioned avoidance response
  • Phencyclidine
  • δFosB

ASJC Scopus subject areas

  • Behavioral Neuroscience

Cite this

Asenapine sensitization from adolescence to adulthood and its potential molecular basis. / Shu, Qing; Qin, Rongyin; Chen, Yingzhu; Hu, Gang; Li, Ming.

In: Behavioural Brain Research, Vol. 273, 15.10.2014, p. 166-176.

Research output: Contribution to journalArticle

Shu, Qing ; Qin, Rongyin ; Chen, Yingzhu ; Hu, Gang ; Li, Ming. / Asenapine sensitization from adolescence to adulthood and its potential molecular basis. In: Behavioural Brain Research. 2014 ; Vol. 273. pp. 166-176.
@article{7c093a607a84472c83b4ed4d6a487aca,
title = "Asenapine sensitization from adolescence to adulthood and its potential molecular basis",
abstract = "Asenapine is a new antipsychotic drug that induces a long-lasting behavioral sensitization in adult rats. The present study investigated the developmental impacts of adolescent asenapine treatment on drug sensitivity and on 3 proteins implicated in the action of antipsychotic drugs (i.e. brain-derived neurotrophic factor (BDNF), dopamine D2 receptor, and δFosB) in adulthood. Male adolescent Sprague-Dawley rats (postnatal days, P 43-48) were first treated with asenapine (0.05, 0.10 or 0.20mg/kg, sc) and tested in the conditioned avoidance or PCP (2.0mg/kg, sc)-induced hyperlocomotion tasks for 5 days. After they became adults (~P 76), asenapine sensitization was assessed in a single avoidance or PCP-induced hyperlocomotion challenge test with all rats being injected with asenapine (0.10mg/kg, sc). Rats were then sacrificed 1 day later and BDNF, D2 and δFosB in the prefrontal cortex, striatum and hippocampus were examined using Western blotting. In adolescence, repeated asenapine treatment produced a persistent and dose-dependent inhibition of avoidance response, spontaneous motor activity and PCP-induced hyperlocomotion. In the asenapine challenge test, adult rats treated with asenapine (0.10 and 0.20mg/kg) in adolescence made significantly fewer avoidance responses and showed a stronger inhibition of spontaneous motor activity than those previously treated with saline. However, no group difference in the levels of BDNF, D2 and δFosB expression was found. These findings suggest that although adolescent asenapine treatment for a short period of time induces a robust behavioral sensitization that persists into adulthood, such a long-term effect is not likely to be mediated by BDNF, D2 and δFosB.",
keywords = "Asenapine, BDNF, Conditioned avoidance response, Phencyclidine, δFosB",
author = "Qing Shu and Rongyin Qin and Yingzhu Chen and Gang Hu and Ming Li",
year = "2014",
month = "10",
day = "15",
doi = "10.1016/j.bbr.2014.07.042",
language = "English (US)",
volume = "273",
pages = "166--176",
journal = "Behavioural Brain Research",
issn = "0166-4328",
publisher = "Elsevier",

}

TY - JOUR

T1 - Asenapine sensitization from adolescence to adulthood and its potential molecular basis

AU - Shu, Qing

AU - Qin, Rongyin

AU - Chen, Yingzhu

AU - Hu, Gang

AU - Li, Ming

PY - 2014/10/15

Y1 - 2014/10/15

N2 - Asenapine is a new antipsychotic drug that induces a long-lasting behavioral sensitization in adult rats. The present study investigated the developmental impacts of adolescent asenapine treatment on drug sensitivity and on 3 proteins implicated in the action of antipsychotic drugs (i.e. brain-derived neurotrophic factor (BDNF), dopamine D2 receptor, and δFosB) in adulthood. Male adolescent Sprague-Dawley rats (postnatal days, P 43-48) were first treated with asenapine (0.05, 0.10 or 0.20mg/kg, sc) and tested in the conditioned avoidance or PCP (2.0mg/kg, sc)-induced hyperlocomotion tasks for 5 days. After they became adults (~P 76), asenapine sensitization was assessed in a single avoidance or PCP-induced hyperlocomotion challenge test with all rats being injected with asenapine (0.10mg/kg, sc). Rats were then sacrificed 1 day later and BDNF, D2 and δFosB in the prefrontal cortex, striatum and hippocampus were examined using Western blotting. In adolescence, repeated asenapine treatment produced a persistent and dose-dependent inhibition of avoidance response, spontaneous motor activity and PCP-induced hyperlocomotion. In the asenapine challenge test, adult rats treated with asenapine (0.10 and 0.20mg/kg) in adolescence made significantly fewer avoidance responses and showed a stronger inhibition of spontaneous motor activity than those previously treated with saline. However, no group difference in the levels of BDNF, D2 and δFosB expression was found. These findings suggest that although adolescent asenapine treatment for a short period of time induces a robust behavioral sensitization that persists into adulthood, such a long-term effect is not likely to be mediated by BDNF, D2 and δFosB.

AB - Asenapine is a new antipsychotic drug that induces a long-lasting behavioral sensitization in adult rats. The present study investigated the developmental impacts of adolescent asenapine treatment on drug sensitivity and on 3 proteins implicated in the action of antipsychotic drugs (i.e. brain-derived neurotrophic factor (BDNF), dopamine D2 receptor, and δFosB) in adulthood. Male adolescent Sprague-Dawley rats (postnatal days, P 43-48) were first treated with asenapine (0.05, 0.10 or 0.20mg/kg, sc) and tested in the conditioned avoidance or PCP (2.0mg/kg, sc)-induced hyperlocomotion tasks for 5 days. After they became adults (~P 76), asenapine sensitization was assessed in a single avoidance or PCP-induced hyperlocomotion challenge test with all rats being injected with asenapine (0.10mg/kg, sc). Rats were then sacrificed 1 day later and BDNF, D2 and δFosB in the prefrontal cortex, striatum and hippocampus were examined using Western blotting. In adolescence, repeated asenapine treatment produced a persistent and dose-dependent inhibition of avoidance response, spontaneous motor activity and PCP-induced hyperlocomotion. In the asenapine challenge test, adult rats treated with asenapine (0.10 and 0.20mg/kg) in adolescence made significantly fewer avoidance responses and showed a stronger inhibition of spontaneous motor activity than those previously treated with saline. However, no group difference in the levels of BDNF, D2 and δFosB expression was found. These findings suggest that although adolescent asenapine treatment for a short period of time induces a robust behavioral sensitization that persists into adulthood, such a long-term effect is not likely to be mediated by BDNF, D2 and δFosB.

KW - Asenapine

KW - BDNF

KW - Conditioned avoidance response

KW - Phencyclidine

KW - δFosB

UR - http://www.scopus.com/inward/record.url?scp=84905976665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905976665&partnerID=8YFLogxK

U2 - 10.1016/j.bbr.2014.07.042

DO - 10.1016/j.bbr.2014.07.042

M3 - Article

VL - 273

SP - 166

EP - 176

JO - Behavioural Brain Research

JF - Behavioural Brain Research

SN - 0166-4328

ER -